145 related articles for article (PubMed ID: 36176817)
1. Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study.
Ma L; Platnick S; Platnick H
Cureus; 2022 Aug; 14(8):e28442. PubMed ID: 36176817
[TBL] [Abstract][Full Text] [Related]
2. CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature.
Bilge S; Ekici B
J Cannabis Res; 2021 Dec; 3(1):53. PubMed ID: 34911567
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Family Implications of Cannabidiol (CBD)-Dominant Full-Spectrum Phytocannabinoid Extract in Children and Adolescents with Moderate to Severe Non-Syndromic Autism Spectrum Disorder (ASD): An Observational Study on Neurobehavioral Management.
Mazza JAS; Ferreira LS; Martins-Vieira AF; Beserra DDL; Rodrigues VA; Malcher-Lopes R; Caixeta FV
Pharmaceuticals (Basel); 2024 May; 17(6):. PubMed ID: 38931353
[TBL] [Abstract][Full Text] [Related]
4. Effects of CBD-Enriched
Fleury-Teixeira P; Caixeta FV; Ramires da Silva LC; Brasil-Neto JP; Malcher-Lopes R
Front Neurol; 2019; 10():1145. PubMed ID: 31736860
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid treatment for the symptoms of autism spectrum disorder.
Aran A; Cayam Rand D
Expert Opin Emerg Drugs; 2024 Mar; 29(1):65-79. PubMed ID: 38226593
[TBL] [Abstract][Full Text] [Related]
6. Individually tailored dosage regimen of full-spectrum Cannabis extracts for autistic core and comorbid symptoms: a real-life report of multi-symptomatic benefits.
Montagner PSS; Medeiros W; da Silva LCR; Borges CN; Brasil-Neto J; de Deus Silva Barbosa V; Caixeta FV; Malcher-Lopes R
Front Psychiatry; 2023; 14():1210155. PubMed ID: 37671290
[TBL] [Abstract][Full Text] [Related]
7. Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety.
Stolar O; Hazan A; Vissoker RE; Kishk IA; Barchel D; Lezinger M; Dagan A; Treves N; Meiri D; Berkovitch M; Kohn E; Heyman E
Front Pharmacol; 2022; 13():977484. PubMed ID: 36249785
[No Abstract] [Full Text] [Related]
8. Autism Spectrum Disorder and Mental Health Comorbidity Leading to Prolonged Inpatient Admission.
Gupta S; Caskey A; Soares N; Augustyn M
J Dev Behav Pediatr; 2018; 39(6):523-525. PubMed ID: 30045160
[TBL] [Abstract][Full Text] [Related]
9. Cannabidiol and cannabis-inspired terpene blends have acute prosocial effects in the BTBR mouse model of autism spectrum disorder.
Staben J; Koch M; Reid K; Muckerheide J; Gilman L; McGuinness F; Kiesser S; Oswald IWH; Koby KA; Martin TJ; Kaplan JS
Front Neurosci; 2023; 17():1185737. PubMed ID: 37397463
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ
Peters EN; MacNair L; Mosesova I; Christians U; Sempio C; Klawitter J; Land MH; Ware MA; Turcotte C; Bonn-Miller MO
Eur J Clin Pharmacol; 2022 Feb; 78(2):259-265. PubMed ID: 34664109
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications.
Holdman R; Vigil D; Robinson K; Shah P; Contreras AE
Cannabis Cannabinoid Res; 2022 Aug; 7(4):451-463. PubMed ID: 34432543
[No Abstract] [Full Text] [Related]
12. Effects of daily Δ
Withey SL; Kangas BD; Charles S; Gumbert AB; Eisold JE; George SR; Bergman J; Madras BK
Drug Alcohol Depend; 2021 Apr; 221():108629. PubMed ID: 33640678
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol as a suggested candidate for treatment of autism spectrum disorder.
Poleg S; Golubchik P; Offen D; Weizman A
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():90-96. PubMed ID: 30171992
[TBL] [Abstract][Full Text] [Related]
14. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV
Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report.
Shannon S; Opila-Lehman J
Integr Med (Encinitas); 2015 Dec; 14(6):31-5. PubMed ID: 26807069
[TBL] [Abstract][Full Text] [Related]
16. Implications of the endocannabinoid system and the therapeutic action of cannabinoids in autism spectrum disorder: A literature review.
de Camargo RW; de Novais Júnior LR; da Silva LM; Meneguzzo V; Daros GC; da Silva MG; de Bitencourt RM
Pharmacol Biochem Behav; 2022 Nov; 221():173492. PubMed ID: 36379443
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats.
Malone DT; Jongejan D; Taylor DA
Pharmacol Biochem Behav; 2009 Aug; 93(2):91-6. PubMed ID: 19393686
[TBL] [Abstract][Full Text] [Related]
18. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial.
Silva EAD; Medeiros WMB; Santos JPMD; Sousa JMM; Costa FBD; Pontes KM; Borges TC; Espínola C; Andrade E Silva AH; Nunes ELG; Alves NT; Rosa MDD; Albuquerque KLGD
Trends Psychiatry Psychother; 2024; 46():e20210396. PubMed ID: 35617670
[TBL] [Abstract][Full Text] [Related]
20. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
